I agree that this site is using cookies. You can find further informations here.
X
Yasutoshi Kuboki
110  results:
Search for persons X
?
1

Whole‐transcriptome sequencing in advanced gastric or gastr..:

Hashimoto, Tadayoshi ; Nakamura, Yoshiaki ; Mishima, Saori...
Cancer Science.  115 (2024)  5 - p. 1622-1633 , 2024
Link: https://doi.org/10.1111/..
 
?
2

Multiomic molecular characterization of the response to com..:

Takei, Shogo ; Tanaka, Yosuke ; Lin, Yi-Tzu...
Journal for ImmunoTherapy of Cancer.  12 (2024)  2 - p. e008210 , 2024
Link: https://doi.org/10.1136/..
 
?
3

Exploratory Biomarker Analysis Using Plasma Angiogenesis-Re..:

Sunakawa, Yu ; Kuboki, Yasutoshi ; Watanabe, Jun...
Targeted Oncology.  19 (2024)  1 - p. 59-69 , 2024
Link: https://doi.org/10.1007/..
 
?
4

A phase 1/1b, open-label, dose-escalation study of PD-1 inh..:

Yamamoto, Noboru ; Kuboki, Yasutoshi ; Harano, Kenichi...
Investigational New Drugs.  , 2024
Link: https://doi.org/10.1007/..
 
?
5

PD‐1 inhibition with retifanlimab and/or arginase inhibitio..:

Kuboki, Yasutoshi ; Koyama, Takafumi ; Matsubara, Nobuaki...
Cancer Medicine.  13 (2024)  8 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
6

Sotorasib with panitumumab in chemotherapy-refractory KRASG..:

Kuboki, Yasutoshi ; Fakih, Marwan ; Strickler, John...
Nature Medicine.  30 (2024)  1 - p. 265-270 , 2024
Link: https://doi.org/10.1038/..
 
?
7

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patie..:

Fujiwara, Yutaka ; Kuboki, Yasutoshi ; Furukawa, Masayuki...
Cancer Medicine.  12 (2023)  9 - p. 10597-10611 , 2023
Link: https://doi.org/10.1002/..
 
?
8

Safety and tolerability of first‐line durvalumab with treme..:

Lee, Dae Ho ; Kim, Hye Ryun ; Keam, Bhumsuk...
Cancer Medicine.  12 (2023)  15 - p. 16066-16075 , 2023
Link: https://doi.org/10.1002/..
 
?
9

Trifluridine/tipiracil with or without bevacizumab in metas..:

Yoshino, Takayuki ; Taieb, Julien ; Kuboki, Yasutoshi...
Therapeutic Advances in Medical Oncology.  15 (2023)  - p. 175883592211461 , 2023
Link: https://doi.org/10.1177/..
 
?
10

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidi..:

Kuboki, Yasutoshi ; Terazawa, Tetsuji ; Masuishi, Toshiki...
British Journal of Cancer.  128 (2023)  10 - p. 1897-1905 , 2023
Link: https://doi.org/10.1038/..
 
?
11

First‐in‐human study of E7130 (a tumor microenvironment‐ame..:

Doi, Toshihiko ; Matsubara, Nobuaki ; Naito, Yoichi...
Cancer.  129 (2023)  15 - p. 2348-2359 , 2023
Link: https://doi.org/10.1002/..
 
?
12

Quantitative Analysis of the Concentration of Trifluridine ..:

Koganemaru, Shigehiro ; Fuchigami, Hirobumi ; Yamashita, Hiroki...
Clinical Pharmacology & Therapeutics.  115 (2023)  1 - p. 62-70 , 2023
Link: https://doi.org/10.1002/..
 
?
13

Efficacy and safety of trifluridine/tipiracil plus ramuciru..:

Okunaka, Mashiro ; Kawazoe, Akihito ; Nakamura, Hitomi...
Gastric Cancer.  26 (2023)  6 - p. 1030-1039 , 2023
Link: https://doi.org/10.1007/..
 
?
14

A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody..:

Doi, Toshihiko ; Kuboki, Yasutoshi ; Naito, Yoichi...
Cancer Science.  113 (2022)  3 - p. 1010-1017 , 2022
Link: https://doi.org/10.1111/..
 
?
15

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Mult..:

Yukami, Hiroki ; Kawazoe, Akihito ; Lin, Yi-Tzu...
Clinical Cancer Research.  28 (2022)  16 - p. 3480-3488 , 2022
Link: https://doi.org/10.1158/..
 
1-15